AZN 240913 81.00C (AZN240913C81000) Stock Options, News & Quotes

US OptionsDetailed Quotes

AZN240913C81000

Watchlist

0.37
+0.29+362.50%

15min DelayTrading Sep 13 09:36 ET

0.37High0.37Low

Intraday

5D
Daily

News

AstraZeneca, Daiichi Sankyo Reports Safety Profile of Breast Cancer Drug in Phase 3b/4 Study
MT NewswiresSep 13 10:59 ET
AstraZeneca Chair Shows Confidence With Share Purchase
TipRanksSep 13 10:47 ET
AstraZeneca, Roche Cut at Deutsche After Trial Readouts for Key Drugs
Seeking AlphaSep 13 10:40 ET
Express News | AstraZeneca And Daiichi Sankyo To Present Findings Of ENHERTU Showing Clinical Activity In Patients With HER2 Positive Metastatic Breast Cancer And Brain Metastases
BenzingaSep 13 10:03 ET
ENHERTU (Fam-trastuzumab Deruxtecan-nxki) Showed Substantial Clinical Activity in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastases
BusinesswireSep 13 10:00 ET
AstraZeneca Stock Downgraded on Drug Trial Results
Schaeffer's Investment ResearchSep 13 09:20 ET

Comments

Movers and Shakers

6 hours ago

Columns Today's Morning Movers and Top Ratings | ADBE, ORCL, MRNA and More

Morning Movers
Gapping up
$Oracle (ORCL.US)$ Shares of Oracle surged over 6.2% as the company increased its revenue forecast for fiscal 2026 and provided strong guidance for the fiscal year 2029.
$Restoration Hardware (RH.US)$ Shares of the home furnishings retailer jumped 18.9% following a robust second quarter. RH reported adjusted earnings per share of $1.69 on revenue of $830 million, surpassing analysts' expectations of $1.56 p...

JovishehMY

Sep 5 09:22

Share Your Profit/Loss

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?

Ryand83

Aug 10 16:18

$LumiraDx (LMDXF.US)$ I think whatever $ROCHE HOLDING AG (RHHBY.US)$ intends to do is going to be massive. Owning 75% or more of the company float means at the bare minimum if this were say a 50B deal Roche would only essentially lose out maximum 10B. I'm just thinking to myself if the other pharmas $AstraZeneca (AZN.US)$ & the other one got a piece of this 🥧 too.

CHFANTA

Aug 1 09:54

$AstraZeneca (AZN.US)$ you can do better~